

# World Journal of *Hepatology*

*World J Hepatol* 2023 April 27; 15(4): 441-584



**REVIEW**

- 441** COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations  
*Roshanshad R, Roshanshad A, Fereidooni R, Hosseini-Bensenjan M*
- 460** Recent advances in recurrent hepatocellular carcinoma therapy  
*Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX*
- 477** Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes  
*Alomari M, Rashid MU, Chadalavada P, Ragheb J, Zafar H, Suarez ZK, Khazaaleh S, Gonzalez AJ, Castro FJ*
- 497** Emerging concepts in the care of patients with cirrhosis and septic shock  
*Jimenez JV, Garcia-Tsao G, Saffo S*

**MINIREVIEWS**

- 515** Ablative strategies for recurrent hepatocellular carcinoma  
*Wang L, Liu BX, Long HY*
- 525** Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis  
*Garbuzenko DV*
- 538** Morphological aspects of small-duct cholangiopathies: A minireview  
*Sticova E, Fabian O*

**ORIGINAL ARTICLE**

**Retrospective Study**

- 554** Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States  
*Lee IS, Okumura K, Misawa R, Sogawa H, Veillette G, John D, Diflo T, Nishida S, Dhand A*
- 564** Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations: A new challenge on the horizon in the United States  
*Dahiya DS, Jahagirdar V, Ali H, Gangwani MK, Aziz M, Chandan S, Singh A, Perisetti A, Soni A, Inamdar S, Sanaka MR, Al-Haddad M*

**Observational Study**

- 577** Clinicopathological features of 11 cases of chronic hepatitis B infection complicated with primary biliary cholangitis  
*Ye Y, Zhang Q, Lu ZH, Tan YW*

**ABOUT COVER**

Editorial Board Member of *World Journal of Hepatology*, Nouhoum Bouare, DSc, PhD, Research Scientist, Biomedical Research, National Institute of Public Health, Bamako 1771, Mali. nbouare@insp.ml

**AIMS AND SCOPE**

The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJH* mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

**INDEXING/ABSTRACTING**

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yi-Xuan Cai, Production Department Director: Xiang Li, Editorial Office Director: Xiang Li.

**NAME OF JOURNAL**

*World Journal of Hepatology*

**ISSN**

ISSN 1948-5182 (online)

**LAUNCH DATE**

October 31, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

**EDITORIAL BOARD MEMBERS**

<https://www.wjnet.com/1948-5182/editorialboard.htm>

**PUBLICATION DATE**

April 27, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Retrospective Study

# Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations: A new challenge on the horizon in the United States

Dushyant Singh Dahiya, Vinay Jahagirdar, Hassam Ali, Manesh Kumar Gangwani, Muhammad Aziz, Saurabh Chandan, Amandeep Singh, Abhilash Perisetti, Aakriti Soni, Sumant Inamdar, Madhusudhan R Sanaka, Mohammad Al-Haddad

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B, B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Shiryajev YN, Russia; Sitkin S, Russia; Thapar P, India

**Received:** January 7, 2023

**Peer-review started:** January 7, 2023

**First decision:** February 21, 2023

**Revised:** February 24, 2023

**Accepted:** March 27, 2023

**Article in press:** March 27, 2023

**Published online:** April 27, 2023



**Dushyant Singh Dahiya**, Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI 48601, United States

**Vinay Jahagirdar**, Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO 64110, United States

**Hassam Ali**, Department of Internal Medicine, East Carolina University, Greenville, NC 27858, United States

**Manesh Kumar Gangwani**, Department of Internal Medicine, The University of Toledo, Toledo, OH 43606, United States

**Muhammad Aziz**, Department of Gastroenterology, The University of Toledo, Toledo, OH 43606, United States

**Saurabh Chandan**, Division of Gastroenterology and Hepatology, CHI Creighton University Medical Center, Omaha, NE 68131, United States

**Amandeep Singh, Madhusudhan R Sanaka**, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH 44195, United States

**Abhilash Perisetti**, Division of Gastroenterology and Hepatology, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, United States

**Aakriti Soni**, Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA 01608, United States

**Sumant Inamdar**, Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States

**Mohammad Al-Haddad**, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States

**Corresponding author:** Dushyant Singh Dahiya, MD, Doctor, Department of Internal Medicine, Central Michigan University College of Medicine, 1015 S Washington Ave, Third Floor, Saginaw, MI 48601, United States. [dush.dahiya@gmail.com](mailto:dush.dahiya@gmail.com)

## Abstract

### BACKGROUND

Peptic ulcer disease (PUD) is frequently seen in patients with liver cirrhosis. However, current literature lacks data on PUD in non-alcoholic fatty liver disease (NAFLD) hospitalizations.

### AIM

To identify trends and clinical outcomes of PUD in NAFLD hospitalizations in the United States.

### METHODS

The National Inpatient Sample was utilized to identify all adult ( $\geq 18$  years old) NAFLD hospitalizations with PUD in the United States from 2009-2019. Hospitalization trends and outcomes were highlighted. Furthermore, a control group of adult PUD hospitalizations without NAFLD was also identified for a comparative analysis to assess the influence of NAFLD on PUD.

### RESULTS

The total number of NAFLD hospitalizations with PUD increased from 3745 in 2009 to 3805 in 2019. We noted an increase in the mean age for the study population from 56 years in 2009 to 63 years in 2019 ( $P < 0.001$ ). Racial differences were also prevalent as NAFLD hospitalizations with PUD increased for Whites and Hispanics, while a decline was observed for Blacks and Asians. The all-cause inpatient mortality for NAFLD hospitalizations with PUD increased from 2% in 2009 to 5% in 2019 ( $P < 0.001$ ). However, rates of *Helicobacter pylori* (*H. pylori*) infection and upper endoscopy decreased from 5% in 2009 to 1% in 2019 ( $P < 0.001$ ) and from 60% in 2009 to 19% in 2019 ( $P < 0.001$ ), respectively. Interestingly, despite a significantly higher comorbidity burden, we observed lower inpatient mortality (2% *vs* 3%,  $P = 0.0004$ ), mean length of stay (LOS) (11.6 *vs* 12.1 d,  $P < 0.001$ ), and mean total healthcare cost (THC) (\$178598 *vs* \$184727,  $P < 0.001$ ) for NAFLD hospitalizations with PUD compared to non-NAFLD PUD hospitalizations. Perforation of the gastrointestinal tract, coagulopathy, alcohol abuse, malnutrition, and fluid and electrolyte disorders were identified to be independent predictors of inpatient mortality for NAFLD hospitalizations with PUD.

### CONCLUSION

Inpatient mortality for NAFLD hospitalizations with PUD increased for the study period. However, there was a significant decline in the rates of *H. pylori* infection and upper endoscopy for NAFLD hospitalizations with PUD. After a comparative analysis, NAFLD hospitalizations with PUD had lower inpatient mortality, mean LOS, and mean THC compared to the non-NAFLD cohort.

**Key Words:** Non-alcoholic fatty liver disease; Peptic ulcer disease; Trends; Outcomes; Mortality

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Due to dietary and lifestyle changes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is on the rise worldwide. Peptic ulcer disease (PUD) is commonly seen in patients with liver cirrhosis. However, data on PUD in NAFLD hospitalizations is currently lacking. In this study, we noted an increase in inpatient mortality for NAFLD hospitalizations with PUD in the United States. The rates of *Helicobacter pylori* infection and upper endoscopy for NAFLD hospitalizations with PUD were on the decline. Despite a higher comorbidity burden, inpatient mortality, mean length of stay, and mean total healthcare cost were lower for NAFLD hospitalizations with PUD compared to the non-NAFLD cohort.

**Citation:** Dahiya DS, Jahagirdar V, Ali H, Gangwani MK, Aziz M, Chandan S, Singh A, Perisetti A, Soni A, Inamdar S, Sanaka MR, Al-Haddad M. Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations: A new challenge on the horizon in the United States. *World J Hepatol* 2023; 15(4): 564-576

**URL:** <https://www.wjgnet.com/1948-5182/full/v15/i4/564.htm>

**DOI:** <https://dx.doi.org/10.4254/wjh.v15.i4.564>

## INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) encompasses a wide range of conditions primarily charac-



terized by the presence of hepatic steatosis which is identified on radiological imaging or histology after other secondary causes of fat deposition have been excluded[1]. Based on histological findings, it is further subdivided into NAFL, which is hepatic steatosis without hepatocellular injury, and non-alcoholic steatohepatitis (NASH) characterized by hepatic steatosis and inflammation with hepatocyte injury. NAFLD usually progresses linearly from steatosis and hepatitis to fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Risk factors commonly implicated in the development of NAFLD include obesity, diabetes mellitus, hypertriglyceridemia, and metabolic syndrome[2]. The global prevalence of NAFLD is estimated to be 25% and is expected to rise further due to the rising incidence and prevalence of obesity worldwide[3]. In the United States, approximately 80 million people have NAFLD, with NASH being the second leading cause of liver transplant[4].

Peptic ulcer disease (PUD) involves acid-induced mucosal disruption in the upper gastrointestinal (GI) tract, usually in the stomach or proximal duodenum. *Helicobacter pylori* (*H. pylori*) infection and the excessive use of non-steroidal anti-inflammatory drugs are the leading causes of PUD[5]. Additionally, increasing age, smoking, alcohol use, and obesity have a strong association with PUD[6]. Although the prevalence of self-reported physician-diagnosed ulcer disease in the United States was as high as 10% at the end of the 20<sup>th</sup> century, there has been a decrease in prevalence and hospitalizations for PUD in the last few decades, primarily due to advancements in *H. pylori* eradication and increasing utilization of proton pump inhibitors for acid suppression[7,8].

The association between alcoholic liver disease and PUD has been well established with studies reporting a higher prevalence of PUD in patients with alcoholic liver cirrhosis[9]. Additionally, a study by Nojkov and Cappell noted that PUD was the most common cause of non-variceal hemorrhage in cirrhotics and carried a higher rate of re-bleeding, delayed ulcer healing, and recurrence when compared to the general population[10]. However, there continue to be significant knowledge gaps on PUD in NAFLD hospitalizations. Hence, we addressed the knowledge gaps in current literature as we identified hospitalization trends, outcomes, and predictors of mortality for NAFLD hospitalizations with PUD. Furthermore, we also performed a comparative analysis between NAFLD hospitalizations with PUD and non-NAFLD PUD hospitalizations to determine the influence of NAFLD on PUD.

## MATERIALS AND METHODS

### **Design and data source**

The study cohort was derived from the National Inpatient Sample (NIS) database which is one of the largest, publicly available, multi-ethnic databases in the United States. The NIS, part of the Healthcare Cost and Utilization Project group of databases, consists of data on inpatient admissions submitted by hospitals across the United States to state-wide data organizations, covering 97% of the United States population[11]. It approximates a 20-percent stratified sample, and the dataset is weighted to obtain national estimates[12]. For the 2009-2019 study period, the NIS database was coded using the International Classification of Diseases (ICD)-9/10 coding systems.

### **Study population**

We utilized the NIS to obtain all adult ( $\geq 18$  years) NAFLD hospitalizations with PUD in the United States from 2009-2019. Furthermore, a control group of all adult PUD hospitalizations without NAFLD were identified for comparative analysis.

### **Statistical analysis and outcome measures**

Statistical analysis was conducted using SAS 9.4 (SAS Institute Inc, Cary, NC) while accounting for the weights in the stratified survey design. The weights were considered during statistical estimation by incorporating variables for strata, clusters, and weight to discharges in the NIS. Descriptive statistics were provided, including mean (standard deviation) for continuous variables and count (percentage) for categorical variables. To test for the trend for proportions of binary variables in years, the Cochran-Armitage trend test was implemented. The trend for the averages of continuous variables in years was examined using linear regression. The Rao-Scott design-adjusted chi-square test, which takes the stratified survey design into account, examined the association between two categorical variables. All analytical results were statistically significant when the *P*-values  $\leq 0.05$ .

### **Ethical considerations**

The NIS database lacks any patient and hospital-specific identifiers. Hence, this study was exempt from Institutional Review Board (IRB) review as per guidelines put forth by our institutional IRB for research on database studies.

## RESULTS

### **Hospitalization characteristics for NAFLD hospitalizations with PUD**

Overall, there was no decline in the total number of NAFLD hospitalizations with PUD (3745 in 2009 to 3805 in 2019, with a peak of 6885 in 2014) (Table 1). The mean age increased from 56.0 years in 2009 to 63.0 years in 2019 ( $P < 0.001$ ), with a significant increase noted for the 65-79 age group (26% in 2009 to 46% in 2019). A majority of NAFLD hospitalizations with PUD were for females and Whites. Racial differences were also noted as there was a declining trend of NAFLD hospitalizations with PUD for Blacks from 10% in 2009 to 5% in 2019 ( $P = 0.01$ ) and Asians from 3% in 2009 to 2% in 2019 ( $P = 0.01$ ), while Whites and Hispanics had a rising trend (Table 1 and Figure 1). Furthermore, rates of *H. pylori* infection and upper endoscopy decreased from 2009 to 2019 (Table 1). Most NAFLD hospitalizations with PUD were at large hospitals, and admissions in urban teaching hospitals increased from 40% in 2009 to 80% in 2019 ( $P < 0.001$ ). Overall, Medicare was the largest insurer for NAFLD hospitalizations with PUD.

### **Outcomes for NAFLD hospitalizations with PUD**

We noted a rising trend of all-cause inpatient mortality for NAFLD hospitalizations with PUD from 2% in 2009 to 5% in 2019 ( $P < 0.001$ ) (Table 2). However, inpatient mortality for Whites declined from 81% in 2009 to 64% in 2019 ( $P = 0.04$ ) within the race analysis. We did not find a statistically significant trend for mean length of stay (LOS) and mean total healthcare cost (THC). Furthermore, the rates of GI tract perforation decreased [33% (2009) to 8% (2019),  $P = 0.02$ ] but the proportion of patients with GI bleeding increased [0% (2009) to 11% (2019),  $P = 0.04$ ].

### **Comparative analysis of NAFLD and non-NAFLD hospitalizations with PUD**

NAFLD hospitalizations with PUD were younger (58.6 vs 65.3 years,  $P < 0.001$ ), and had more Whites and Hispanics compared to the non-NAFLD subgroup (Table 3). A Charlson Comorbidity Index (CCI)  $\geq 3$  was noted in a higher proportion of NAFLD hospitalizations with PUD (55%) compared to non-NAFLD PUD hospitalizations (49%) ( $P < 0.001$ ). Although NAFLD hospitalizations with PUD had a higher proportion of patients that underwent upper endoscopy (49% vs 41%,  $P < 0.001$ ), the rates of *H. pylori* infection was not statistically different between the cohorts (Table 3).

Despite a higher CCI score, the all-cause inpatient mortality was lower (2% vs 3%,  $P = 0.0004$ ), for NAFLD-PUD hospitalizations compared to the non-NAFLD-PUD hospitalizations (Table 4). Furthermore, the mean LOS was shorter (11.6 vs 12.1 d,  $P < 0.001$ ), the and mean THC was lower (\$178598 and \$184727,  $P < 0.001$ ) for NAFLD-PUD hospitalizations compared to non-NAFLD-PUD hospitalizations (Table 4). There was no statistical difference in the proportion of patients with complications such as GI bleeding and perforation between the 2 groups.

### **Predictors of mortality for NAFLD hospitalizations with PUD**

Significant predictors of all-cause inpatient mortality for NAFLD hospitalizations with PUD included GI tract perforation (aHR = 2.71, 95%CI: 1.37-5.35,  $P = 0.004$ ), coagulopathy (aHR = 2.24, 95%CI: 0.74-0.84,  $P < 0.001$ ), fluid and electrolyte disorders (aHR = 1.92, 95%CI: 1.82-2.01,  $P < 0.001$ ), alcohol abuse (aHR = 1.51, 95%CI: 1.42-1.61,  $P < 0.001$ ), and protein-calorie malnutrition (aHR = 1.16, 95%CI: 1.11-1.22,  $P < 0.001$ ) (Table 5).

## DISCUSSION

PUD is believed to be the most common cause of non-variceal GI bleeding in liver cirrhosis patients. However, data on PUD in NAFLD hospitalizations is lacking. Ours is the only study in current literature that evaluates the trends of hospitalization characteristics and outcomes for NAFLD hospitalizations with PUD and further compares NAFLD hospitalizations with PUD to non-NAFLD PUD hospitalizations using the NIS database. In this study, we did not find a decline in the total number of NAFLD hospitalizations with PUD. The all-cause inpatient mortality increased from 2% in 2009 to 5% in 2019 in the United States. However, the rates of upper endoscopy and *H. pylori* infection declined for NAFLD hospitalizations with PUD. Furthermore, NAFLD hospitalizations with PUD had lower mortality, LOS, and THC compared to the non-NAFLD group, despite a higher comorbidity burden. An understanding of the trends, outcomes, and influence of NAFLD on PUD is crucial as it may help gastroenterologists identify individuals at the greatest risk of adverse outcomes and complications, thereby preventing morbidity and mortality.

Recent studies have demonstrated a dramatic increase in the prevalence and hospitalization rates for patients with NAFLD, which could have led to the slightly increased number of hospitalizations noted in our study[13,14]. This is despite the fact that there has been an overall decline in hospitalization rates for PUD in the United States[15]. Furthermore, racial differences have also been noted in NAFLD hospitalizations for ethnic minorities. Per current literature, the highest and lowest rates of NAFLD

**Table 1 Hospitalization trends for non-alcoholic fatty liver disease hospitalizations with peptic ulcer disease in the United States from 2009-2019**

Variable	Years									
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Total hospitalizations	3745	4563	5230	5655	5759	6885	5745	2880	3070	3430
Mean age (yr)	56.01 ± 0.8	57.07 ± 0.75	56.68 ± 0.81	57.1 ± 0.14	57.1 ± 0.41	57.4 ± 0.59	57.5 ± 0.97	62.4 ± 0.41	62.8 ± 0.8	63.7 ± 0.74
Age groups, yr (%)										
18-34	9	8	8	8	7	8	8	3	4	2
35-49	25	24	25	25	23	22	21	12	11	15
50-64	39	42	41	39	42	42	39	44	40	36
65-79	26	25	26	27	28	28	32	42	44	47
≥ 80	< 1	1	1	1	< 1	< 1	< 1	1	1	1
Gender (%)										
Male	45	42	43	43	44	44	45	36	40	40
Female	55	48	57	58	56	56	55	64	60	50
Race (%)										0.01
White	72	73	70	71	72	71	70	74	76	76
Black	10	8	9	10	9	11	10	6	5	5
Hispanic	11	13	14	13	12	11	13	14	15	15
Asian	3	3	3	3	2	3	3	2	2	2
Native American	1	< 1	1	1	1	1	1	2	1	1
Other	3	3	3	3	3	4	3	3	2	4
CCI (%)										
CCI = 0	0	0	0	0	0	0	0	0	0	0
CCI = 1	34	32	34	32	32	31	31	6	6	6
CCI = 2	27	24	23	22	22	22	25	13	8	10
CCI ≥ 3	39	44	43	47	46	47	44	86	86	86
Hospital region (%)										
Northeast	13	12	14	16	15	14	14	13	13	16
Midwest	24	24	22	22	22	21	21	28	29	29
South	39	41	43	21	42	43	44	38	37	35
West	24	23	21	21	21	21	21	20	21	19
Hospital bed-size (%)										
Small	8	11	11	13	11	16	16	15	16	16
Medium	25	25	22	29	26	32	29	24	25	28
Large	67	64	67	59	63	52	55	61	59	56
Hospital location and teaching status (%)										
Rural	8	10	11	10	10	7	7	6	5	5
Urban non-teaching	47	50	45	41	37	26	27	21	20	14
Urban teaching	46	40	44	49	53	67	66	73	75	81
Primary payer										
Medicare	41	42	41	44	43	44	44	53	60	60



Medicaid	13	15	14	15	15	16	16	14	11	11
Private	36	35	35	33	34	33	33	30	25	26
Other	10	8	10	8	8	7	7	2	3	3
Median household income (%)										
1 <sup>st</sup> (0-25 <sup>th</sup> )	26	27	30	28	31	28	31	31	27	29
2 <sup>nd</sup> (26 <sup>th</sup> -50 <sup>th</sup> )	25	24	25	24	26	29	24	27	32	32
3 <sup>rd</sup> (51 <sup>st</sup> -75 <sup>th</sup> )	30	24	24	26	24	23	26	24	25	21
4 <sup>th</sup> (76 <sup>th</sup> -100 <sup>th</sup> )	19	24	21	22	19	20	19	17	15	18
Upper endoscopy (%)	60	59	62	58	59	59	62	20	22	18

CCI: Charlson Comorbidity Index.

**Table 2 Trends of outcomes for non-alcoholic fatty liver disease hospitalizations with peptic ulcer disease in the United States from 2009-2019**

Outcome	Years											P value
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	
Inpatient mortality (%)	2	1	2	2	2	2	1	4	4	5	5	< 0.001
Gender-specific inpatient mortality (%)												0.2
Male	25	21	28	57	53	38	40	37	52	32	31	
Female	75	79	72	43	47	62	60	63	48	48	48	
Race-specific inpatient mortality (%)												0.4
White	81	53	89	48	79	73	73	71	81	61	64	
Black	7	0	0	14	0	4	0	4	4	6	11	
Hispanic	12	47	11	19	16	19	7	17	8	19	14	
Asian	0	0	0	10	5	0	0	4	0	3	6	
Native American	0	0	0	5	0	0	7	0	4	3	6	
Others	0	0	0	5	0	4	13	4	4	6	0	
Age-group specific inpatient mortality (%)												0.1
18-34	7	0	0	0	0	3	0	0	0	0	0	
35-49	13	26	16	13	0	17	14	9	22	14	6	
50-64	51	36	33	31	29	34	36	41	52	31	48	
65-79	28	24	36	56	71	41	50	50	26	48	45	
≥ 80	0	13	14	0	0	3	0	0	0	3	0	
Length of stay (d)	17.1 ± 0.59	11.8 ± 0.76	16.3 ± 0.58	9.2 ± 0.85	9.0 ± 0.01	8.2 ± 0.68	10.1 ± 0.33	9.6 ± 0.49	17.3 ± 0.33	9.2 ± 0.90	11.2 ± 0.22	0.06
Total hospital charge (\$)	182296 ± 760	104265 ± 620	215085 ± 130	172837 ± 170	157079 ± 890	105031 ± 760	136876 ± 800	134573 ± 730	373045 ± 450	143284 ± 940	174044 ± 550	0.8
Complications (%)												
Bleeding	0	21	0	0	5	10	7	17	7	10	11	0.4
Perforation	33	12	35	29	16	3	13	17	11	3	8	0.02

**Table 3 Comparative analysis of hospitalization characteristics for non-alcoholic fatty liver disease hospitalizations with peptic ulcer disease and non-NAFLD hospitalizations with peptic ulcer disease in the United States from 2009-2019**

	NAFLD hospitalizations with PUD	Non-NAFLD hospitalizations with PUD	P value
Total hospitalizations	50769 (1%)	4624628 (99%)	
Mean age (yr)	58.6 ± 0.27	65.3 ± 0.80	< 0.001
Age group, yr (%)			< 0.001
18-34	6	6	
35-49	21	15	
50-64	40	33	
65-79	32	40	
≥ 80	1	6	
Gender (%)			< 0.001
Male	42	49	
Female	48	51	
Race (%)			< 0.001
White	72	70	
Black	9	14	
Hispanic	13	9	
Asian	3	3	
Native American	1	1	
Other	3	3	
CCI (%)			< 0.001
CCI = 0	0	0	
CCI = 1	25	30	
CCI = 2	20	22	
CCI ≥ 3	55	49	
Upper endoscopy (%)	49	41	< 0.001
<i>H. pylori</i> (%)	3	3	0.5
Hospital region (%)			< 0.001
Northeast	14	18	
Midwest	24	23	
South	41	39	
West	21	20	
Hospital bed size (%)			< 0.001
Small	14	16	
Medium	27	28	
Large	59	56	
Hospital location and teaching status (%)			< 0.001
Rural	8	10	
Urban nonteaching	32	34	
Urban teaching	60	56	
Expected primary payer (%)			< 0.001
Medicare	47	61	

Medicaid	14	12	
Private	32	21	
Other	7	5	
Median household income (quartile) (%)			< 0.001
1 <sup>st</sup> (0-25 <sup>th</sup> )	29	31	
2 <sup>nd</sup> (26 <sup>th</sup> -50 <sup>th</sup> )	27	26	
3 <sup>rd</sup> (51 <sup>st</sup> -75 <sup>th</sup> )	25	24	
4 <sup>th</sup> (76 <sup>th</sup> -100 <sup>th</sup> )	20	19	

CCI: Charlson Comorbidity Index; NAFLD: Non-alcoholic fatty liver disease; PUD: Peptic ulcer disease.

**Table 4 Comparative analysis of outcomes for non-alcoholic fatty liver disease hospitalizations with peptic ulcer disease and non-NAFLD hospitalizations with peptic ulcer disease in the United States from 2009-2019**


Outcomes	NAFLD hospitalizations with PUD	Non-NAFLD hospitalizations with PUD	P value
Inpatient mortality (%)	2	3	0.0004
Gender-specific inpatient mortality (%)			< 0.001
Male	38	54	
Female	62	46	
Race-specific inpatient mortality (%)			< 0.001
White	70	72	
Black	6	12	
Hispanic	16	9	
Asian	3	4	
Native American	3	1	
Others	3	3	
Age-group specific inpatient mortality (%)			< 0.001
18-34	1	2	
35-49	13	7	
50-64	39	30	
65-79	44	49	
≥ 80	2	12	
Length of stay (d)	11.6	12.1	< 0.001
Total healthcare cost (\$)	178598	184727	< 0.001
Complications (%)			
Bleeding	8	6	0.2
Perforations	14	18	0.1

NAFLD: Non-alcoholic fatty liver disease; PUD: Peptic ulcer disease.

hospitalizations are for Hispanics and African Americans, respectively[13,16]. This has been attributed to dietary habits, lifestyle, and genetics as Hispanics have an allele of the patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) that favors hepatic fat storage, while African Americans possess a different allele of the same gene associated with lower hepatic fat content[17,18]. Our study echoed similar findings as we noted a rising trend of NAFLD hospitalizations with PUD for Hispanics from 11% in 2009 to 15% in 2019 ( $P = 0.01$ ) and a declining trend for Blacks from 10% in 2009 to 5% in 2019 ( $P = 0.01$ ). These racial differences are important as we advocate for the need for aggressive public health

**Table 5 Predictors of all-cause inpatient mortality for non-alcoholic fatty liver disease hospitalizations with peptic ulcer disease in the United States from 2009-2019**

Variable	Adjusted hazard ratio	95% confidence interval	P value
Coagulopathy	2.24	2.14-2.34	< 0.001
Obesity	0.79	0.74-0.84	< 0.001
Protein calorie malnutrition	1.16	1.11-1.22	< 0.001
Fluid and electrolyte disorder	1.92	1.82-2.01	< 0.001
Alcohol abuse	1.51	1.42-1.61	< 0.001
Perforation	2.71	1.37-5.35	0.004

**Figure 1 Racial trends for non-alcoholic fatty liver disease hospitalizations with peptic ulcer disease in the United States from 2009-2019.**

measures for Hispanic populations to increase awareness about the burden of PUD in those who have NAFLD. Moreover, hospitalists and gastroenterologists who take care of NAFLD hospitalizations should have a high degree of suspicion of PUD in these patients.

In the United States, there has been a significant increase in inpatient mortality for NAFLD-cirrhosis by 32% between 2005-2015, despite a decrease in the inpatient mortality rates for patients with all other causes of liver cirrhosis[19]. However, there has been a significant decline in inpatient PUD mortality due to the increasing use of therapeutic endoscopic procedures for bleeding ulcers[20]. In our study, there was a rising trend of all-cause inpatient mortality for NAFLD hospitalizations with PUD (Table 2). From a race perspective, we noted an increasing trend of all-cause inpatient mortality for Blacks and Hispanics, while a decline was observed for Whites. The exact reasons for these findings are unknown, but they may, in part, be attributed to a higher comorbidity burden and the increasing mean age for NAFLD hospitalizations with PUD, particularly for ethnic minorities *i.e.*, Blacks and Hispanics (Table 1), leading to greater severity of disease and adverse outcomes. Interestingly, we noted lower all-cause inpatient mortality, mean LOS, and mean THC for NAFLD hospitalizations with PUD compared to non-NAFLD PUD hospitalizations, despite a higher comorbidity burden. But there was no statistical difference in the proportion of patients with complications such as GI bleeding and perforation between the two groups. The exact reason for this protective effect of NAFLD is unclear and needs further investigation by multi-center prospective studies.

There has been a rapid decline in *H. pylori* infection rates in the western world secondary to higher standards of living and improved hygiene[21]. An analysis of outpatient endoscopy centers in the United States noted a significant fall in *H. pylori* infections from 11% in 2009 to 9% in 2018[22]. However,

a recent cross-sectional study identified a positive relationship between *H. pylori* infection and NAFLD in females after adjusting for metabolic variables, gastrin factors, and liver enzymes[23]. This implies that rates of *H. pylori* infection may rise with an increasing prevalence of NAFLD. Our study contradicts these findings as we observed a declining trend of *H. pylori* infection in NAFLD hospitalizations with PUD (Table 1). Furthermore, we also noted a decline in the trends of utilization of upper endoscopy from 60% in 2009 to 19% in 2019. This may be due to increased adherence to guideline-directed management which advocates for non-endoscopic testing for uninvestigated dyspepsia without alarm features in individuals < 60 years of age[24]. However, due to an increasing trend of all-cause inpatient mortality in this subset population, it may be justified to perform upper endoscopy at an early stage to prevent adverse clinical outcomes. Interestingly, NAFLD hospitalizations with PUD had a higher proportion of patients that underwent upper endoscopy compared to non-NAFLD PUD hospitalizations. The exact reason for this is currently unknown and needs further investigation.

Our study has numerous strengths and some limitations. A key strength of this study is the study population, which is derived from one of the largest, publicly available, all-payer, multi-ethnic databases in the United States. An analysis over the 11-year study period allowed us to obtain meaningful information on the trends of hospitalization characteristics and outcomes for NAFLD hospitalizations with PUD, adding to scarce literature. Moreover, through our unique and multifaceted comparative analysis, we were able to determine the influence of NAFLD on PUD. Furthermore, as the NIS database covers 97% of the United States population, the results of our study are applicable to almost all NAFLD hospitalizations with PUD, offering a national perspective. However, we do acknowledge the limitations associated with our study. This was a retrospective study design which is subject to all biases associated with retrospective studies. The NIS database does not contain information on the severity, time from hospitalization to discharge, hospital course, and other treatment aspects of the disease. Lastly, the NIS is an administrative database maintained through data collection organizations that use the ICD coding system to store inpatient data. Hence, the possibility of human coding errors cannot be excluded. However, despite these limitations, we believe that the large sample size and a comprehensive analysis technique help us better understand the trends, characteristics, and outcomes of NAFLD hospitalizations with PUD, and promote future research on the topic.

## CONCLUSION

NAFLD is a public health concern and places a significant burden on the United States healthcare system. There is a significant knowledge gap on PUD in patients with NAFLD who are admitted to the hospital. We noted an increase the all-cause inpatient mortality for NAFLD hospitalizations with PUD in the United States between 2009-2019. There was a rising trend of NAFLD hospitalizations with PUD for Hispanics, reflecting the need for urgent public health measures to increase awareness in this subset population. Compared to non-NAFLD PUD hospitalizations, NAFLD hospitalizations with PUD had lower inpatient mortality, mean LOS, and mean THC despite a higher comorbidity burden. However, there was no statistical difference in GI bleeding and perforation between the two groups. Perforation of the GI tract, coagulopathy, alcohol abuse, malnutrition, and fluid and electrolyte disorders were identified to be independent predictors of all-cause inpatient mortality for NAFLD hospitalizations with PUD. Additional multi-center prospective studies are needed to further confirm these findings.

## ARTICLE HIGHLIGHTS

### Research background

The association between peptic ulcer disease (PUD) and liver cirrhosis has been thoroughly investigated. However, there are knowledge gaps on PUD in non-alcoholic fatty liver disease (NAFLD) hospitalizations. As the prevalence of NAFLD continues to rise across the globe and in the United States, it is vital to identify individuals with NAFLD at high risk of adverse clinical outcomes from PUD.

### Research motivation

In current literature, there is a knowledge gap on PUD in NAFLD hospitalizations. Hence, this study was designed to help fill the knowledge gaps that currently exist in this subset population.

### Research objectives

Our main objective was to identify national trends in hospitalization characteristics, clinical outcomes, and complications for NAFLD hospitalizations with PUD. We also performed a comparative analysis between NAFLD and non-NAFLD hospitalizations with PUD to assess the influence of NAFLD on PUD.



## Research methods

The National Inpatient Sample was used from 2009-2019 to identify all adult ( $\geq 18$  years) NAFLD hospitalizations with PUD in the United States. Furthermore, a control group of all adult PUD hospitalizations without NAFLD were identified for comparative analysis. Statistical analysis was conducted using SAS 9.4. To test for the trend for proportions of binary variables, the Cochran-Armitage trend test was implemented. The trend for the averages of continuous variables in years was examined using linear regression. The Rao-Scott design-adjusted chi-square test examined the association between two categorical variables.

## Research results

NAFLD-PUD hospitalizations increased from 3745 (2009) to 3805 (2019). Racial differences were noted as NAFLD hospitalizations with PUD increased for Whites and Hispanics, while a decline was observed for Blacks and Asians. There was an increase in all-cause inpatient mortality for NAFLD hospitalizations with PUD from 2% in 2009 to 5% in 2019 ( $P < 0.001$ ). However, the rates of *Helicobacter pylori* (*H. pylori*) infection and upper endoscopy decreased during the study period. Despite a high comorbidity burden, we observed lower inpatient mortality, mean length of hospital stay, and mean total healthcare cost (THC) for NAFLD-PUD hospitalizations *vs* the non-NAFLD-PUD cohort. Perforation of the gastrointestinal tract, coagulopathy, alcohol abuse, malnutrition, and fluid and electrolyte disorders were identified as independent predictors of inpatient mortality for NAFLD hospitalizations with PUD.

## Research conclusions

Between 2009-2019, inpatient mortality for NAFLD hospitalizations with PUD increased. However, there was a significant decline in *H. pylori* infections and esophagogastroduodenoscopy for NAFLD-PUD hospitalizations. After a comparative analysis, NAFLD-PUD hospitalizations had lower rates of mortality, mean length of hospital stay, and mean THC *vs* the non-NAFLD-PUD cohort despite a higher comorbidity burden.

## Research perspectives

This is one of the few national studies which investigates trends, clinical outcomes, and complications of NAFLD hospitalizations with PUD, using one of the largest, multi-ethnic databases in the United States. Future research should be directed toward identifying the underlying cause of racial disparities for this subset population.

## FOOTNOTES

**Author contributions:** Dahiya DS, Ali H, Inamdar S, Sanaka MR, and Al-Haddad M were responsible for the conception and design; Dahiya DS, Inamdar S, Sanaka MR, and Al-Haddad M provided administrative support; Dahiya DS and Ali H were responsible for provision, collection, and assembly of data; all authors were responsible for review of literature, drafting the manuscript, and revision of key components of the manuscript; and all authors have read and approve the final version of the manuscript.

**Institutional review board statement:** The National Inpatient Sample database contains numerous safeguards to protect patient privacy. It also lacks patient- and hospital-specific identifiers. Therefore, our study was exempt from Institutional Review Board (IRB) evaluation as per guidelines put forth by our institutional IRB for analysis of HCUP databases.

**Informed consent statement:** The data for this study was collected from the National Inpatient Sample (NIS) database. As the NIS database lacks patient-specific and hospital-specific identifiers, this study did not require informed consent.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The National Inpatient Sample is a publicly available database that can be accessed at <https://www.hcup-us.ahrq.gov>. Due to the availability of a large sample size within the NIS database, it is an ideal choice for the estimation of national trends and clinical outcomes.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** United States

**ORCID number:** Dushyant Singh Dahiya 0000-0002-8544-9039; Vinay Jahagirdar 0000-0001-6685-1033; Hassam Ali 0000-0001-5546-9197; Manesh Kumar Gangwani 0000-0002-3931-6163; Saurabh Chandan 0000-0002-2661-6693; Amandeep Singh 0000-0001-8581-1408; Abhilash Perisetti 0000-0003-4074-6395; Aakriti Soni 0000-0001-9732-2898; Sumant Inamdar 0000-0002-1002-2823; Madhusudhan R Sanaka 0000-0003-2506-8602; Mohammad Al-Haddad 0000-0003-1641-9976.

**S-Editor:** Wang JJ

**L-Editor:** A

**P-Editor:** Cai YX

## REFERENCES

- 1 Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. *Clin Liver Dis (Hoboken)* 2012; **1**: 99-103 [PMID: 31186860 DOI: 10.1002/cld.81]
- 2 Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). *Hepatol Int* 2013; **7** Suppl 2: 755-764 [PMID: 26202291 DOI: 10.1007/s12072-013-9480-x]
- 3 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]
- 4 Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015; **148**: 547-555 [PMID: 25461851 DOI: 10.1053/j.gastro.2014.11.039]
- 5 Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. Risk Factors for the Presence of Symptoms in Peptic Ulcer Disease. *Clin Endosc* 2017; **50**: 578-584 [PMID: 28008163 DOI: 10.5946/ce.2016.129]
- 6 Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. *Digestion* 2011; **84**: 102-113 [PMID: 21494041 DOI: 10.1159/000323958]
- 7 Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. *Am J Public Health* 1996; **86**: 200-205 [PMID: 8633736 DOI: 10.2105/ajph.86.2.200]
- 8 Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. *BMC Gastroenterol* 2022; **22**: 58 [PMID: 35144540 DOI: 10.1186/s12876-022-02130-2]
- 9 Siringo S, Burroughs AK, Bolondi L, Muia A, Di Febo G, Miglioli M, Cavalli G, Barbara L. Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. *J Hepatol* 1995; **22**: 633-641 [PMID: 7560857 DOI: 10.1016/0168-8278(95)80219-3]
- 10 Nojkov B, Cappell MS. Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis. *World J Gastroenterol* 2016; **22**: 446-466 [PMID: 26755890 DOI: 10.3748/wjg.v22.i1.446]
- 11 Healthcare Cost and Utilization Project. Introduction to the HCUP National Inpatient Sample (NIS). [cited 3 December 2022]. Available from: [https://www.hcup-us.ahrq.gov/db/nation/nis/NIS\\_Introduction\\_2018.jsp](https://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2018.jsp)
- 12 Houchens R, Ross, D, Elixhauser A. Nationwide Inpatient Sample (NIS) Redesign Final Report (2014). [cited 3 December 2022]. Available from: <http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp>
- 13 Adejumo AC, Samuel GO, Adegba OM, Adejumo KL, Ojelabi O, Akanbi O, Ogundipe OA, Pani L. Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States. *Ann Gastroenterol* 2019; **32**: 504-513 [PMID: 31474798 DOI: 10.20524/aog.2019.0402]
- 14 Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. *Hepatology* 2017; **65**: 2100-2109 [PMID: 28103626 DOI: 10.1002/hep.29068]
- 15 Feinstein LB, Holman RC, Yorita Christensen KL, Steiner CA, Swerdlow DL. Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. *Emerg Infect Dis* 2010; **16**: 1410-1418 [PMID: 20735925 DOI: 10.3201/eid1609.091126]
- 16 Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. *Hepatol Commun* 2021; **5**: 1676-1688 [PMID: 34558817 DOI: 10.1002/hep4.1760]
- 17 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. *Clin Gastroenterol Hepatol* 2016; **14**: 5-12; quiz e9 [PMID: 25976180 DOI: 10.1016/j.cgh.2015.05.001]
- 18 Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]
- 19 Zou B, Yeo YH, Jeong D, Park H, Sheen E, Lee DH, Henry L, Garcia G, Ingelsson E, Cheung R, Nguyen MH. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. *Dig Dis Sci* 2020; **65**: 1520-1528 [DOI: 10.1007/s10620-019-05869-z]
- 20 Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. *Ann Surg* 2010; **251**: 51-58 [PMID: 20009753 DOI: 10.1097/SLA.0b013e3181b975b8]
- 21 Parsonnet J. The incidence of Helicobacter pylori infection. *Aliment Pharmacol Ther* 1995; **9** Suppl 2: 45-51 [PMID: 8547528]
- 22 Sonnenberg A, Turner KO, Genta RM. Low Prevalence of Helicobacter pylori-Positive Peptic Ulcers in Private Outpatient Endoscopy Centers in the United States. *Am J Gastroenterol* 2020; **115**: 244-250 [PMID: 31972622 DOI: 10.14309/ajg.0000000000000517]

- 23 **Wang J**, Dong F, Su H, Zhu L, Shao S, Wu J, Liu H. H. pylori is related to NAFLD but only in female: A Cross-sectional Study. *Int J Med Sci* 2021; **18**: 2303-2311 [PMID: [33967606](#) DOI: [10.7150/ijms.50748](#)]
- 24 **Chey WD**, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol* 2017; **112**: 212-239 [PMID: [28071659](#) DOI: [10.1038/ajg.2016.563](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

